Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Isao Teshirogi Ph.D. | CEO, President & Chairman | 1.89M | -- | 1959 |
| Susumu Mitsumori | Vice President of Finance & Accounting Department | -- | -- | -- |
| Dr. Ryuichi Kiyama Ph.D. | Senior Executive Officer & Senior VP of Administration Division | -- | -- | -- |
| Mr. Takeshi Shiota Ph.D. | Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div. | -- | -- | -- |
| Mr. Yoshimasa Kyokawa | Vice President of Corporate Communications & Secretary Office | -- | -- | -- |
| Yoshihiro Furuya | Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office | -- | -- | -- |
| Mr. Kohji Hanasaki Ph.D. | Senior Executive Officer and Senior VP of Supply Supervisory Unit | -- | -- | -- |
| Dr. John A. Keller Ph.D. | Senior Executive Officer and Senior VP of R&D Supervisory Unit | -- | -- | 1965 |
| Mr. Kazuhiro Hatanaka | Senior Executive Officer & Senior VP of Corporate Strategy Division | -- | -- | -- |
| Akira Kato Ph.D. | Senior Executive Officer & President of Shionogi Pharma Co., Ltd | -- | -- | -- |
Shionogi & Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 4,959
Description
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Corporate Governance
Upcoming Events
January 29, 2025 at 4:00 AM UTC - February 3, 2025 at 4:00 AM UTC
Shionogi & Co., Ltd. Earnings Date
Recent Events
March 27, 2024 at 12:00 AM UTC
Ex-Dividend Date
December 17, 2019 at 12:00 AM UTC
Dividend Date